What is Colgate-Palmolive's latest dividend and current dividend yield?

What guidance did Colgate-Palmolive's management provide for the next earnings period?

What is the market's earnings forecast for Colgate-Palmolive next quarter?

Did Colgate-Palmolive beat or miss consensus estimates last quarter?

What were the key takeaways from Colgate-Palmolive's earnings call?

What were the key takeaways from Colgate-Palmolive’s earnings call?

What is the revenue and EPS growth rate for Colgate-Palmolive year over year?

What factors drove the changes in Colgate-Palmolive's revenue and profit?

- **Q4 Growth**: Organic sales up 3% (ex-private label), driven by emerging markets and Hill's innovation. 
- **2030 Strategy**: Emphasizes premiumization, AI, and supply chain efficiency to offset category slowdowns.
- **Regional分化**: Latin America (+5% Brazil, Mexico), Asia (India recovery), vs. North America lagging.
- **Financial Strength**: $4.2B free cash flow, 1-4% 2026 guidance reflects cautious outlook.
- **Key Risks**: North America consumer uncertainty, FX volatility, and competitive promotional activity.

**【CEO Summary Section】**
- **Q4 2025 Results**: Organic sales growth of 3% (excluding private label), driven by emerging markets and improved momentum in all categories except North America. Net sales, gross profit, and EPS grew year-over-year despite challenges like raw material inflation and tariffs.
- **2030 Strategy Focus**: Accelerating investment in innovation, omnichannel demand generation, AI-driven capabilities, and supply chain optimization. Key areas include premiumization, science-based innovation, and digital transformation.
- **Regional Performance**: 
  - **North America**: Struggling with category slowdowns, but showing sequential improvement. Volume growth in Hill's and premiumization efforts.
  - **Latin America**: Strong growth in Brazil and Mexico, with sequential improvement in Andina and Central America.
  - **Asia**: India returning to growth, Hawley & Hazel gaining share in e-commerce.
  - **Europe**: Mixed performance, with Western Europe improving but Eastern Europe lagging.

**【CFO Financial Commentary】**
- **Financial Highlights**: GAAP net income of $1.2 billion, Non-GAAP EPS of $1.08 (vs. $0.95 prior year). Free cash flow up 12% to $4.2 billion. FX expected to contribute low single-digit revenue growth in 2026, primarily in H1.
- **Cost Management**: Operating expenses down 5% YoY, with focus on RGM and innovation investments.
- **2026 Guidance**: Organic sales growth of 1-4% (wide range due to category uncertainty). FX to be reinvested in growth initiatives and margin expansion.

**【Q&A Key Highlights】**
- **North America Challenges**: Soft consumer demand, pantry destocking, and competitive couponing. Strategy includes premium innovation and RGM to offset volume declines.
- **Emerging Markets Strength**: Latin America and Asia outperforming developed markets. Brazil and India seeing strong growth despite macro challenges.
- **Hill's Performance**: Volume growth of 5% (ex-private label), driven by therapeutic products and share gains. Expansion plans in fresh pet food segment.
- **FX Flexibility**: CFO notes FX benefits will be used for advertising, product placement, and margin protection, with no reliance on FX for long-term growth.
- **M&A Strategy**: Focus on science-driven, high-margin adjacencies like fresh pet food. Prime100 acquisition in Australia performing ahead of expectations.

Colgate-Palmolive Company (CL) Q4 2025 Earnings Call Transcript

- **Organic Growth**: 1.2% for the year, driven by emerging markets and premiumization. Q3 growth of 1.7% despite global category slowdown.
- **Strategic Initiatives**: AI adoption in marketing and R&D, with generative AI pilots showing early success. $200-300M restructuring to fund innovation.
- **Financial Resilience**: Non-GAAP EPS maintained at $1.08 despite 40-50bp gross margin hit. Q4 expected to improve with destocking resolution.
- **Key Risks**: Consumer uncertainty, raw material inflation, and trade destocking. Private label exit impacting 2025 growth but benefiting 2026 margins.
- **Hill's Momentum**: 2.5% organic growth ex-private label, with wet and cat segments outperforming. Prescription Diet business driving margin expansion.

**【CEO Summary Section】**
- **Global Performance**: Organic sales growth of 1.2% for the year, with Q3 growth of 1.7% despite a challenging market environment. North America saw sequential improvement, while Europe and Latin America faced headwinds from pricing and volume dynamics.
- **2030 Strategy Focus**: Accelerated innovation, AI adoption (e.g., generative AI for marketing and R&D), and supply chain efficiency to drive growth. Emphasis on premiumization and emerging markets (e.g., China, India) for long-term expansion.
- **Challenges**: Consumer uncertainty, raw material inflation (palm oil), and trade destocking. Private label exit reduced organic growth by 70 basis points.
- **Hill's Performance**: 2.5% organic growth ex-private label, driven by wet and cat segments. Prescription Diet business outperformed, offsetting category slowdown.

**【CFO Financial Commentary】**
- **Q3 Results**: GAAP net income of $420 million, Non-GAAP EPS of $1.08 (vs. $1.05 prior year). Gross margin declined 40-50 basis points due to Colgate Total formula change costs and raw material inflation.
- **Guidance**: Full-year organic growth in line with Q3 (1.2%), with Q4 expected to improve due to destocking resolution and reduced private label impact. FX tailwinds in Q4 offsetting prior year headwinds.
- **Cost Management**: SGPP program to deliver savings and fund innovation, with $200-300 million restructuring charges over three years.

**【Q&A Highlights】**
- **Latin America**: Colgate Total formula change impacted 150 basis points of organic growth, but re-launch in Brazil and Mexico shows early recovery. Pricing moderating in Andina, Central America.
- **India**: GST reduction benefiting oral care category, but urban demand sluggish. Focus on premiumization and rural penetration.
- **AI & Innovation**: AI hubs for generative content, agnostic AI for supply chain, and core innovation pipeline to stimulate demand across price tiers.
- **Pet Food**: Hill's gaining share in wet and cat segments, despite category slowdown. Private label exit to improve margins in 2026.


Colgate-Palmolive Company (CL) Q3 2025 Earnings Call Transcript

- **Q2 Growth Resilience**: 2.4% organic sales growth vs. 1.8% in Q1, driven by North America recovery and pricing execution.
- **AI & Innovation Investment**: $200-300M productivity program to accelerate RGM, AI, and 2030 strategy.
- **Hill's Outperformance**: 5% organic growth vs. flat category, led by therapeutic and wet pet food innovation.
- **Margin Guidance**: 2025 gross margin flat, with $75M tariff savings offset by $100M+ raw material inflation.
- **U.S. Category Caution**: Consumer spending soft, but pricing and innovation (Colgate Miracle Repair) driving share gains.

**【CEO Summary Section】**
- Q2 organic sales growth of 2.4% (up 60bps vs. Q1), driven by North America and Africa/Eurasia volume recovery and pricing execution.
- Key initiatives: AI-driven revenue growth management (RGM), price-pack architecture optimization, and $200-300M productivity program over 3 years to fund innovation and 2030 strategy.
- Challenges: High raw material costs (+420bps vs. Q2 2024), FX headwinds, and cautious consumer spending in North America.
- Hill's Pet Nutrition delivered 5% organic growth, outperforming flat category, with strength in therapeutic and wet pet food segments.

**【CFO Financial Commentary】**
- Q2 GAAP net income: $420M; Non-GAAP EPS: $1.08 (vs. $1.05 consensus).
- Gross margin guidance: Flat for 2025, with $75M tariff savings offset by $100M+ raw material inflation (palm oil, fats/tallows).
- Operating expenses: Flat year-over-year, with disciplined cost management.
- Free cash flow: $300M+ for 2025, supporting dividend and share buybacks.

**【Q&A Key Highlights】**
- **Restructuring Program**: $200-300M charges over 3 years to accelerate innovation, AI, and supply chain efficiency. Savings to fund growth and margin expansion.
- **U.S. Category Growth**: Consumer caution persists, but Colgate expects stabilization in 2H25. Pricing and innovation (e.g., Colgate Miracle Repair) driving share gains.
- **Latin America**: Strong relaunch of core brands (+75 markets), but Brazil and Mexico facing macro challenges. Pricing actions to offset FX impacts.
- **Gross Margin Outlook**: 2025 flat guidance maintained; 3Q/4Q benefits from raw material buy-ahead program.
- **Hill's Performance**: 5% organic growth ex-private label, driven by therapeutic innovation and omnichannel execution. Private label production ceased in July.
- **Asia-Pacific**: India urban market softness offset by e-commerce growth (+500bps share). China Colgate brand strong, but Hawley & Hazel needs channel optimization.

Colgate-Palmolive Company (CL) Q2 2025 Earnings Call Transcript

- **Consumer Volatility Drives Q1 Decline**: Organic sales fell 3% YoY due to weaker demand, with North America and China lagging.
- **Tariff Headwinds**: $200M incremental tariff impact in 2025, requiring supply chain restructuring.
- **Innovation Key to Recovery**: Relaunch of Colgate Total and Hill's Scienceiet aim to rebuild consumer trust and drive growth.
- **Europe Outperforms**: Strong pricing and mix improvements offset broader weakness.
- **China Challenges**: Pet care segment struggles, but Colgate core business shows resilience.

**【CEO Opening Remarks】**
- **Consumer Volatility**: Q1 organic sales declined 3% YoY due to weaker consumer demand, particularly in North America and emerging markets. Sequential category growth slowed in February but showed signs of stabilization in April.
- **Tariff Impact**: Additional tariffs imposed since January 2025 are expected to cost ~$200M in 2025, requiring supply chain adjustments (e.g., alternative sourcing, formula simplification).
- **Innovation Focus**: Relaunch of Colgate Total and Hill's Scienceiet with active biome technology aim to drive brand differentiation and consumer loyalty.
- **Market Performance**: Europe delivered strong pricing and mix improvements, while China faced challenges in pet care but Colgate core business grew mid-single digits.

**【Q&A Key Themes】**
- **North America Recovery**: April showed category improvement, but Q2 expected to remain soft. Management emphasizes value-added innovation (e.g., Total relaunch) to rebuild consumer trust.
- **Pricing Strategy**: Pricing decelerated in Q1 but improved sequentially. Emerging markets (e.g., Latin America) saw targeted price increases to offset inflation. Developed markets focus on premium innovation over promotions.
- **Emerging Markets**: Latin America gained volume and value share despite Argentina's inflation. Africa/Middle East maintained strong market share. China's pet care segment struggled, but Colgate core business performed well.
- **Tariff Mitigation**: $2B+ invested in U.S. supply chain since 2020 provides flexibility. Short-term measures include production shifting; long-term solutions include formula simplification and alternative sourcing.

**【Financial Highlights】**
- **Europe Strength**: Pricing and mix improvements drove strong results, contrasting North America's challenges.
- **China Strategy**: Revised go-to-market plan for pet care business, leveraging innovation to regain momentum.
- **AI Investment**: Continued focus on AI and data analytics to enhance promotional effectiveness and consumer insights.

Colgate-Palmolive (CL)-25 Apr 25-2025 Q1 Earnings call transcript

- **$20B Revenue Milestone**: Achieved 1 year ahead of plan with 6+ years of organic growth. 
- **Profitability Breakthrough**: 70bps gross margin expansion in Q4, 10%+ EPS growth. 
- **Investment Payoff**: $1.1B+ ad spend driving 130bps brand health improvement. 
- **Hill's Momentum**: 3%+ volume growth, 300bps share gain in flat category. 
- **US Manufacturing Leadership**: $2B+ investment in domestic capacity, 40%+ new facilities. 
- **2025 Outlook**: 3%-5% organic growth, continued margin expansion, $4.1B+ cash flow.

**【CEO 2024 Yearly Summary】**
- **Revenue Milestone**: Achieved $20 billion in net sales, one year ahead of strategic plan, with 6 consecutive years of organic sales growth (3%-5% CAGR). 
- **Growth Drivers**: 
  - 8%+ organic growth in Q4 (excluding private label drag), driven by balanced volume and pricing. 
  - Innovation contributed 45% more incremental sales in 2024 vs. 2021. 
- **Profitability**: 
  - Gross margin expanded 70bps in Q4, despite $1.5B+ FX headwinds. 
  - Operating margin improved through productivity initiatives. 
  - EPS grew 10%+ vs. initial guidance. 
- **Strategic Investments**: 
  - Advertising spend up 15% (130bps as % of sales) to $1.1B+ annually. 
  - AI/data capabilities deployed to optimize pricing and promotion. 

**【CFO Financial Highlights】**
- **Top Line**: 
  - Full year organic growth 5.5%, Q4 4.3% (excluding 200bps private label drag). 
  - North America oral care up high-single digits, Latin America +8%. 
- **Margin Expansion**: 
  - Gross margin +70bps in Q4, driven by pricing and productivity. 
  - Operating margin expanded despite $120M+ incremental SG&A. 
- **Cash Flow**: 
  - Record $4.1B operating cash flow. 
  - $1.1B net buybacks, $0.75B dividend, +20% total shareholder return. 

**【Q&A Key Themes】**
1. **Gross Margin Sustainability**: 
   - 2025 guidance for continued expansion via mix shift to higher-margin Oral Care/Hill's. 
   - 2023-2024 gross profit reinvested in capabilities to control SG&A. 
2. **North America Recovery**: 
   - Pricing adjustments in H2 2024 stabilized business, Q4 volume growth ex-skin health +3%. 
   - 2025 focus on innovation (Colgate Total relaunch) to drive category growth. 
3. **Hill's Performance**: 
   - 3%+ volume growth in Q4 (vs. flat category), 300bps market share gain. 
   - Wet pet food and small breed segments driving 2025 growth. 
4. **Tariff Mitigation**: 
   - $2B+ invested in US manufacturing since 2020. 
   - Flexible supply chain with 40%+ new US facilities. 
5. **2030 Strategy Preview**: 
   - Continued focus on innovation, data/AI, and professional endorsements. 
   - Targeting $300M+ middle-class expansion in China/India by 2030.

CL

CL fundamentals

Earnings Call

You can ask Aime